

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

High-affinity agonist binding to C5aR results from a cooperative two-site binding mechanism

Andra C. Dumitru^{1#}, R. N. V. Krishna Deepak^{2#}, Heng Liu^{3#}, Melanie Koehler¹, Cheng Zhang^{3*},
Hao Fan^{2*}, David Alsteens^{1*}

¹Université catholique de Louvain, Louvain Institute of Biomolecular Science and Technology, 1348 Louvain-la-Neuve, Belgium.

²Bioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), Singapore.

³Department of Pharmacology and Chemical Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA15261, USA.

Corresponding authors

*E-mail: david.alsteens@uclouvain.be, chengzh@pitt.edu, fanh@bii.a-star.edu.sg

Keywords

Single-molecule, Atomic force microscopy, FD-based AFM, G-protein-coupled receptors, C5aR, molecular dynamics, ligand-receptor, cooperativity.

24 **Abstract**

25 A current challenge in the field of life sciences is to decipher, in their native environment, the
26 functional activation of cell surface receptors upon binding of complex ligands. Lack of suitable
27 nanoscopic methods has hampered our ability to meet this challenge in an experimental
28 manner. Here, we use for the first time the interplay between atomic force microscopy, steered
29 molecular dynamics and functional assays to elucidate the complex ligand-binding mechanism
30 of C5a with the human G protein-coupled C5a receptor (C5aR). We have identified two
31 independent binding sites acting in concert where the N-terminal C5aR serves as kinetic trap
32 and the transmembrane domain as functional site. Our results corroborate the two-site binding
33 model and clearly identify a cooperative effect between two binding sites within the C5aR. We
34 anticipate that our methodology could be used for development and design of new therapeutic
35 agents to negatively modulate C5aR activity.

36 Introduction

37 The complement C5a anaphylatoxin elicits a variety of immunological responses *in vivo* (Guo
38 and Ward, 2005), such as the stimulated production of pro-inflammatory cytokine by binding
39 to its cognate cell surface receptor, the G-protein-coupled receptor C5a anaphylatoxin
40 chemotactic receptor 1 (C5aR). This interaction has been a topic of interest in the last couple
41 of decades due to its relevance in several inflammatory pathologies, such as asthma, arthritis,
42 sepsis and more recently Alzheimer's disease and cancer (Ward, 2004; Woodruff, Nandakumar
43 *et al.*, 2011; Klos, Wende *et al.*, 2013). However, the binding mechanism of the C5a ligand to
44 C5aR remains poorly understood at the molecular level hampering the development of new
45 therapeutic agents (Monk, Scola *et al.*, 2007; Klos, Wende *et al.*, 2013). A two-site binding
46 mechanism has been suggested, with the C5a rigid core interacting with both the N-terminus
47 and the second extracellular loop of the receptor (called binding site (BS)) (Siciliano, Rollins *et*
48 *al.*, 1994), and the C5a flexible C-terminal fragment interacting with the cavity formed by the
49 seven transmembrane (7-TM) helices and involved in the functional activation of C5aR (called
50 effector site (ES)). On one hand, the main interactions at the BS occur between C5aR sulfonated
51 tyrosine residues (Y11 and Y14) and C5a residues R40, R37 and possibly H15 (Siciliano, Rollins
52 *et al.*, 1994; Farzan, Schnitzler *et al.*, 2001; Huber-Lang, Sarma *et al.*, 2003). On the other hand,
53 the C5a R74 is pointed out as a critical residue in the binding to the ES (Siciliano, Rollins *et al.*,
54 1994; Huber-Lang, Sarma *et al.*, 2003). However, given the absence of the structure of the C5a-
55 C5aR complex, these interactions have never been directly confirmed. In addition, clear and
56 direct evidence of how these two binding sites could act in concert is missing. Understanding
57 this process is likely to illuminate the binding paradigm common to members of the GPCR family
58 that bind large macromolecular ligands.

59 Although high-resolution structures of GPCRs have emerged during the last decades, these
60 structures are just a snapshot of a specific stabilized state frozen in time and space, among a
61 myriad of possible dynamic conformations. Investigating complex binding mechanisms, in
62 particular to receptors having multiple intramolecular binding sites, remains a remarkably
63 difficult task to date. The dynamic nature of these processes requires the development of new
64 methodologies that have the ability to simultaneously quantify and structurally map ligand-
65 receptor interactions at the single-molecule level in a dynamic setting. Atomic force microscopy
66 (AFM) combines high-resolution imaging from the micrometer to the (sub-)nanometer range
67 with the capability to apply and measure wide dynamic force ranges from pico- to

68 nanoNewtons, which is necessary to characterize the broad spectrum of chemical interactions
69 occurring in living systems. Force-distance curve-based atomic force microscopy (FD-based
70 AFM) has established itself as a powerful method for imaging a variety of biological systems at
71 sub-nanometer resolution and to simultaneously extract quantitative parameters such as
72 topography, adhesion, elasticity and stiffness (Dufrene, Martinez-Martin *et al.*, 2013;
73 Pfreundschuh, Alsteens *et al.*, 2015; Rigato, Rico *et al.*, 2015; Dumitru, Conrard *et al.*, 2018;
74 Dumitru, Poncin *et al.*, 2018). Functionalization of the AFM tip with specific ligands allows
75 specific detection of (bio-)chemical interactions, while simultaneously extracting their
76 structural, thermodynamic and kinetic parameters. Here, we use FD-based AFM to unravel the
77 binding mechanism at the two C5aR sites and to decipher roles of these sites in the kinetic and
78 energetic properties of the binding process. For the first time, using our affinity imaging
79 method, we have successfully extracted binding properties of a single ligand at a molecular sub-
80 site level. The combination of AFM with steered molecular dynamics (SMD) simulation and
81 functional assays revealed new perspectives on the role of allosteric interactions from a kinetic,
82 thermodynamic and functional point of view.

83 **Results**

84 **C5aR adopts random orientation after reconstitution in lipid membrane**

85 Before characterizing the binding properties of C5a to C5aR, we imaged purified C5aR
86 reconstituted in liposomes and adsorbed on freshly cleaved mica in buffer solution using FD-
87 based AFM. While membrane receptors embedded in their native cellular membrane always
88 have a unique orientation, they lose this original orientation through the reconstitution steps
89 into liposomes (Pfreundschuh, Alsteens *et al.*, 2015). Within lipid bilayers, embedded receptors
90 can adopt both orientations, having either their extracellular or intracellular side exposed to
91 the AFM tip (**Figure 1A**).

92 To detect the C5aR orientation within the lipid bilayer, we first imaged our sample at high-
93 resolution using FD-based AFM to possibly discriminate topographical characteristics
94 corresponding to one of the two orientations. In FD-based AFM, an oscillating AFM cantilever
95 is continuously approached and retracted from the sample surface in a sinusoidal manner
96 (**Figure 1A**) and for each pixel of the image a force-distance (FD) curve is recorded (**Figure 1B**).

97 The sample topography along with the adhesion can be simultaneously extracted from each FD

98 curve (**Figure 1B**) (Dufrene, Martinez-Martin *et al.*, 2013; Alsteens, Pfreunds Schuh *et al.*, 2015;
99 Dumitru, Poncin *et al.*, 2018). The sample imaged by AFM revealed sparsely distributed C5aR
100 particles protruding away from the lipid bilayer surface (**Figure 1C**). The height of the emergent
101 part of C5aR above the lipid bilayer (protrusion height) as well as its diameter (calculated as the
102 full width at half maximum) were extracted for each particle and plotted in a two-dimensional
103 histogram (2D) (**Figures 1D and E**). A bimodal distribution is observed for the heights, with two
104 peaks centered respectively at 1.1 ± 0.5 nm and 2.8 ± 1.2 nm, while the presence of three main
105 populations can be observed for the diameters, with peaks centered at 8.6 ± 0.4 nm
106 (monomers), 14.1 ± 0.3 nm (dimers) and 23.4 ± 1.2 nm (oligomers) (László, Miklós *et al.*, 2008;
107 Alsteens, Pfreunds Schuh *et al.*, 2015; Liu, Kim *et al.*, 2018). The two peaks of height distribution
108 could represent the heights of the extracellular and the intracellular regions of C5aR protruding
109 from the DOPC/CHS membrane. For the monomers, we clearly observed that both orientations
110 are present without preference (similar density in the 2D-histogram).

111 **Identification of C5aR orientation using affinity imaging**

112 After having evidenced that embedded receptors show different protrusion height from the
113 membrane, we combined topography and affinity imaging using functionalized AFM tips to
114 specifically identify C5aR intracellular and extracellular sides (**Figure 2**). Silicon tips were
115 functionalized with a poly(ethylene glycol) linker (PEG), followed by grafting of *tris-N*-
116 nitrilotriacetic acid (*tris*-NTA) molecules. The individual tetradentate NTA ligand forms a
117 hexagonal complex with Ni^{2+} ions, leaving two remaining binding sites accessible to electron
118 donor nitrogen atoms from the histidine sidechains of the His₈-tag engineered to the terminal
119 end of a polypeptide. To specifically probe one side of the C5aR, we either used the *tris*-NTA-
120 Ni^{2+} tip to target the intracellular side using the His₈-tag present at the C5aR C-terminal end
121 (**Figures 2A-D**), or we further derivatized the *tris*-NTA- Ni^{2+} tip with the endogenous C5a ligand
122 to specifically probe the interaction with the ligand-binding site at the C5aR extracellular side
123 (**Figures 2E-H**). Adhesive events were considered to be specific if they were detected at tip-
124 sample distances of 10 ± 5 nm, corresponding to the length of the extended PEG linker, and
125 when the adhesion force was at least two times higher than the noise level (measured at the
126 baseline of the retraction curve, see **Methods**). Additionally, each specific adhesion event was
127 validated by fitting the extension profile of the PEG linker using the worm-like chain model
128 (Sulchek, Friddle *et al.*, 2006). Representative FD curves are presented in **Figures 2D and H**

129 showing either unspecific/no interaction FD curves (curves 1-2) or specific adhesion events
130 (curve 3). Control experiments using bare tips or an amino-derivatized tip show either no
131 interaction or unspecific adhesion events (**Figure S1A-D**). Finally, blocking experiments using
132 free C5a in solution or injection of EDTA significantly reduces the binding probability,
133 confirming the specificity of both probed interactions (**Figure S1E-H**).

134 For the two types of tip functionalization, the FD curves showing specific adhesion events were
135 analyzed and the interaction force was extracted as well as the height of the C5aR on which the
136 FD curve was recorded. These values were displayed in the form of 2D-histograms of force as
137 a function of height (**Figures 2I and J**). We observed that *tris*-NTA-Ni²⁺ functionalized tips mostly
138 interact with receptors having a protruding height centered at 3.1 ± 1.0 nm together with forces
139 of 125 ± 50 pN, while C5a tips were found to interact specifically with receptors more buried
140 into the membrane (height of 1.7 ± 0.5 nm) and interacting with forces of 110 ± 45 pN.
141 Together, these results confirm that the receptor orientation can be determined using only
142 their protrusion heights as those are significantly different (**Figure 2K**). An overlay of the AFM
143 topography and the specific adhesion events recorded (colored pixels) on the same area with
144 both functionalized tips (C5a tip in red and *tris*-NTA-Ni²⁺ tip in green) reveals the identity of the
145 side exposed to the tip (**Figure 2L**). Receptors having a protrusion height under a threshold of
146 1.75 nm were encircled. Together, these data confirm the possibility to identify with a high-
147 probability (> 95%) the receptors oriented in their native state. Therefore, this height criterion
148 will be used in the following force spectroscopy experiments to validate our measurements and
149 to only probe native state receptors.

150 **C5a is a high-affinity agonist of C5aR**

151 Next, we wanted to characterize C5a ligand binding to C5aR (**Figure 3A**). To this end, we
152 simultaneously recorded FD-based AFM height images and adhesion maps (**Figures 3B and C**)
153 and extracted FD curves located on C5aR having their native orientation (based on our height
154 criterion) (**Figure 3D**). Generally, force-probing methods such as FD-based AFM measure the
155 strength of single bonds under an externally applied force. Described first by the Bell-Evans
156 model (Evans and Ritchie, 1997), an external force stressing a bond reduces the activation-
157 energy barrier toward dissociation and, hence, reduces the lifetime (τ) of the ligand-receptor
158 pair (**Figure 3E**). The model predicts that far from equilibrium, the rupture force (e.g., binding
159 strength) of the ligand-receptor bond is proportional to the logarithm of the loading rate (LR),

160 which describes the force applied over time. Recently, Friddle, Noy and de Yoreo (FNdY)
161 introduced a model to interpret the nonlinearity of the rupture forces measured over a wide
162 range of LRs and suggested that this nonlinearity arises through the re-formation of bonds at
163 small LRs (Friddle, Noy *et al.*, 2012). This model provides direct access to the equilibrium free
164 energy ΔG_{bu} between bound and unbound states (see Methods). The non-linear oscillating
165 approach and retraction movement of the AFM tip with respect to the sample results in a wide
166 variety of velocities explored during the rupture of the bonds established between the ligand
167 derivatized tip and C5aR (**Figure 3F**). To further increase the range of velocities explored, we
168 combined the force-volume (FV) mode at low speed to reach low LRs and FD-based AFM to
169 explore unbinding behavior at high LRs (**Figure 3F**). For each FD showing a specific adhesion
170 event, we extracted the binding force and the LR measured as the slope of the force *versus*
171 time curve just before the rupture (**Figure 3G**). When plotting the resulting binding forces as a
172 function of the LRs (also called dynamic force spectroscopy (DFS) plot) on a semi-logarithmic
173 scale (**Figure 3H**), a non-linear dependency of the force with the loading rate is observed as
174 predicted by the FNdY model. Using this model, we extracted the equilibrium force F_{eq} , as well
175 as thermodynamic and kinetic parameters such as the binding equilibrium free energy ΔG_{bu}
176 and the receptor-ligand half-life $\tau_{0.5}$. An equilibrium force F_{eq} of 46 ± 7 pN, a binding equilibrium
177 free energy ΔG_{bu} of -13.6 ± 4.1 kcal mol⁻¹ and a dissociation constant K_d of ≈ 6.09 nM were
178 found. The dissociation constant was calculated using the relation $\Delta G_{bu} = k_B T \times \ln(0.018 K_d)$ with
179 0.018 l mol⁻¹ being the partial molar volume of water. The K_d estimated using our single-
180 molecule method is the same order of magnitude as previously reported values, ranging from
181 1-10 nM, based on radioactive ligand binding assays (Gerber, Meng *et al.*, 2001; Robertson,
182 Rappas *et al.*, 2018). These results highlight that FD-based AFM was suitable to quantify the
183 kinetic and thermodynamic binding of a large ligand interacting with its receptor via multiple
184 orthosteric sites.

185 **MD simulations identify key residues involved in antagonist binding to C5aR**

186 Although it is thought that C5a binds C5aR through two orthosteric sites, a crystal structure of
187 the C5a-C5aR complex is missing. To better investigate the key residues responsible for the high
188 affinity interaction, we turned our attention to PMX53, a well-known C5aR full antagonist that
189 mimics the structure of the C-terminal segment of C5a (March, Proctor *et al.*, 2004; Monk, Scola
190 *et al.*, 2007; Woodruff, Nandakumar *et al.*, 2011). The C5aR-PMX53 crystal structure (Liu, Kim

191 *et al.*, 2018) has been recently elucidated and we can hypothesize that given their high
192 structural similarities, the cyclic hexapeptide PMX53 and the C-terminal segment interact with
193 C5aR through similar residues. To get more insight into the PMX53-C5aR binding dynamics we
194 performed molecular dynamics (MD) and steered MD (SMD) simulations (**Figure 4**). Over the
195 course of the 300 ns unrestrained MD simulation, the C5aR structure remained stable with no
196 significant structural changes as evidenced from the root-mean-square deviation (RMSD)
197 profile (**Figure S2A**). Apart from the N- and C-terminal regions of C5aR, most of the structural
198 fluctuations were observed primarily in the second extracellular loop (ECL2) region. The termini
199 of TM5 and TM7 with the 7-TM core of the protein remained fairly stable (**Figure S2B**). No major
200 structural rearrangements were observed with respect to the PMX53 molecule, which
201 remained tightly bound to C5aR, forming several hydrogen bonds (**Figure S3A and B**). Key
202 intermolecular interactions between C5aR and PMX53 present in the initial crystal structure
203 such as the D282-R6_{PMX53} salt-bridge remained stable throughout the entire 300 ns (**Figure 4**).
204 The Y258-R6_{PMX53} cation- π interaction was broken (R6_{PMX53} CZ and Y258 ring-centroid distance
205 > 6.0 Å) halfway through the simulation but the two residues remained close to each other
206 (**Figure 4G**). Disruption of the cation- π interaction allowed R6_{PMX53} to interact with D282 in a
207 head-on manner (**Figure 4G and Figure S3C**). W5_{PMX53} and R6_{PMX53} saddled Y258 but did not
208 interact directly during the production run (**Figure 4G and Figure S3C**).

209 **PMX53 dissociates from C5aR in two critical steps**

210 Steered molecular dynamics has been successfully employed for studying biological
211 phenomenon such as stability of α -amyloid protofibrils (Lemkul and Bevan, 2010), substrate
212 translocation by membrane transporters (Shi, Quick *et al.*, 2008), and interaction of GPCR
213 ligands with their cognate receptors (Yuan, Raniolo *et al.*, 2018). We employed SMD or center-
214 of-mass (COM) pulling simulations on the final configuration of the 300 ns equilibrium
215 simulation to gain an atomistic insight into the molecular events that occur during the
216 dissociation of PMX53 from the C5aR binding pocket. Akin to AFM experiments, in the pulling
217 simulations, the bound PMX53 molecule was pulled away from the C5aR binding pocket by
218 applying an external force along the z-axis (**Figures 4A and B and Movie 1**). The force vs. time
219 profile of the pulling simulation is presented in **Figure 4B**. The application of force on the PMX53
220 molecule led to a gradual build-up of force until a critical point was reached that was sufficient
221 to break the key intermolecular interactions to allow the dissociation of the bound molecule.

222 The plot showed two such critical points, a minor drop in force around $t = 308$ ps and a major
223 drop in force around $t = 425$ ps. After the major drop, the PMX53 molecule was mostly
224 unbound. We analyzed the evolution of various intermolecular non-covalent interactions
225 between C5aR and PMX53 during the pulling simulation. The analysis revealed that shortly after
226 $t = 308$ ps time-point numerous hydrogen bonds, almost half of which were formed between
227 the ligand and the residues of the C5aR ECL2 region, were broken, resulting in a brief drop in
228 force (**Figures 4C and H**). Further, the critical D282-R6_{PMX53} salt-bridge and the Y258-R6_{PMX53}
229 cation- π were completely broken around $t = 425$ ps time-point when the pulling force was
230 maximal (**Figures 4D and I**). Following the breakage of these critical interactions, the PMX53
231 molecule adopted a more compact conformation facilitated by the formation of an
232 intramolecular R6_{PMX53}-W5_{PMX53} cation- π interaction (**Figures 4E and J**).

233 We also performed umbrella sampling simulations on the configurations generated from the
234 non-equilibrium SMD trajectories to calculate the free energy profile of the PMX53
235 binding/dissociation events. The weighted histogram analysis method (WHAM) was employed
236 to obtain the potential of mean force (PMF) curve from which the ΔG of PMX53 binding was
237 deduced (**Figure 4F**). Bootstrap analysis was used to estimate the statistical errors, and the
238 average PMF profile along with the corresponding standard deviation values are plotted in
239 **Figure S4**. On the basis of the PMF profile, we obtained a ΔG_{bu} value of -13.8 kcal mol⁻¹.

240 **PMX53 binds to C5aR with a high affinity**

241 In parallel with the pulling simulations, we quantified by FD-based AFM the free-energy
242 landscape of the PMX53-C5aR interaction and the role of the key residues identified by our
243 simulation. To this end, we tethered the high-affinity PMX53 antagonist to the AFM tip and
244 then measured its interactions with C5aR (**Figure S5A**) and two C5aR mutants identified through
245 MD simulation (**Figure S5B,C**). Fitting the experimental data with the FNdY model provided an
246 equilibrium force F_{eq} of 50 ± 9 pN corresponding to a binding equilibrium free energy ΔG_{bu} of -
247 13.7 ± 4.9 kcal mol⁻¹ for PMX53-C5aR interaction. This value is very similar to the value
248 determined by the SMD simulation for the PMX53-C5aR. The affinity is also similar in magnitude
249 to the value determined for the C5a ligand although the latter, due to its large size, interacts
250 on multiple binding sites on the receptor. This observation is probably a result of the PMX53
251 reduced size and the various substitutions (compared to the C5a native C-terminus) that makes
252 it accommodate better within the binding pocket. The PMX53 affinity constant K_d of 4.7 nM is

253 in good agreement with previous studies where values between 1-50 nM were found
254 depending on the species and cell type (Woodruff, Strachan *et al.*, 2001; Seow, Lim *et al.*, 2016).

255 **C5aR^{R175V/Y258V} influences the binding kinetics**

256 Next, we tested C5aR mutations within the ES, as pointed by the above MD and SMD
257 simulations. We designed two C5aR mutants (D282A and R175V/Y258V) located in the ES and
258 mediating direct polar interactions (R175 and D282) or water-mediated polar interactions
259 (R175). We performed several functional assays with the C5aR and the two mutants and
260 observed a strong reduction on the G_i-protein activation in response to increased
261 concentration of C5a (**Figure S5**), confirming the crucial role played by these residues in the
262 modulation of C5aR's functional state. We then probed the interaction by FD-based AFM with
263 the PMX53 on both mutants. Thermodynamic analysis using the FNdY model only revealed a
264 slight reduction of the ΔG_{bu} from -13.7 ± 4.9 kcal mol⁻¹ for the C5aR^{WT} to -13.3 ± 1.0 kcal mol⁻¹
265 for the C5aR^{R175V/Y258V} double mutant (**Figure S5B**). This slight reduction in ΔG_{bu} has also been
266 confirmed by MD and SMD simulations using the PMX53-C5aR^{R175V/Y258V} double mutant system
267 following the same protocol used for the PMX53-C5aR^{WT} system. The most striking observation
268 from the MD simulation of PMX53 with the C5aR double-mutant was the reduction in the
269 number of hydrogen bonds formed between C5aR^{R175V/Y258V} and PMX53, particularly involving
270 residues from ECL2. The R175V mutation causes a 66% reduction in the number of hydrogen
271 bonds formed between ECL2 and PMX53 (1.57 ± 0.91) as compared to the wild-type ($4.62 \pm$
272 0.93 ; **Figure S4E**). The R_{6PMX53}-D282 salt-bridge remained stable throughout the 300ns
273 production run whereas the Y258V mutation caused a change in the stability of the W_{5PMX53}
274 orientation (**Figure S4D**). When PMX53 was pulled away from the double-mutant C5aR using a
275 similar SMD protocol, we observed a marked drop in the force required for the ligand to
276 dissociate (**Figure S4B**). The inter- and intramolecular non-covalent interactions behave in a
277 similar fashion as the wild-type but break much earlier (**Figures S4C-E**). The hydrogen bonds
278 between ECL2 and PMX53 broke much earlier around $t = 200$ ps (**Figure S4E**) as compared to
279 the wild-type ($t = 308$ ps) while the R_{6PMX53}-D282 salt-bridge breaks shortly thereafter, but
280 earlier than the wild-type (**Figure S4D**). The PMF profile for the double-mutant shows a
281 significant drop (~43%) in the height of the energy barrier crossed during PMX53 dissociation
282 (-12.2 kcal mol⁻¹ for double-mutant vs. -21.5 kcal mol⁻¹ for WT) although resulting in a slight
283 reduction (~12%) in ΔG_{bu} (-12.2 kcal mol⁻¹ for double-mutant vs. -13.8 kcal mol⁻¹ for WT) (**Figure**

284 **S4F**). Results from our MD and SMD studies are in good agreement with our experimental data
285 obtained by AFM where we observed a slight decrease in the ΔG_{bu} ($\sim 3\%$) but a much important
286 reduction in residence time ($\sim 40\%$) that can be directly linked with the reduction of the height
287 of the energy barrier crossed during PMX53 dissociation. Altogether, these results suggest that
288 the R175 and Y258 residues play a key role in the kinetics of the interaction while at the same
289 time being less crucial for the thermodynamics.

290 **C5aR^{D282} is critical for binding thermodynamics**

291 Finally, we studied the PMX53 binding to the C5aR^{D282A} mutant by FD-based AFM (**Figure S5C**).
292 The analysis of the DFS plot with the FNdY model revealed a strong reduction of the free energy
293 ($\sim 35\%$) leading to a ΔG_{bu} of -7.7 ± 1.9 kcal mol⁻¹, while the residence time remains unchanged
294 (0.1 ms). MD and SMD simulations were attempted on this mutant, with no success in obtaining
295 convincing results for the umbrella sampling simulations due to largely reduced PMX53-
296 C5aR^{D282A} interactions. Yet, both experimental and simulation experiments suggest a strong
297 reduction of the interactions due to the single point mutation in the receptor, thus underlying
298 the important role of D282 in the stabilization of the PMX53 into the binding pocket.

299 **C5a C-terminus weakly binds C5aR effector site**

300 As PMX53 is a peptide that mimics the structure of the C-terminal segment of C5a, we
301 wondered whether the C-terminal segment of C5a could also bind to the C5aR ES with high-
302 affinity. To prevent the interaction between the core of C5a and the sulfation sites at the BS,
303 the C5aR Δ Tyr mutant with mutations Y11F and Y14F sites was generated (Farzan, Schnitzler *et*
304 *al.*, 2001). The lack of sulfation on the C5aR Δ Tyr mutant was then validated by Western Blot
305 using anti-sulfated tyrosine antibodies (**Figure 5A**). The interaction between the C5a ligand and
306 C5aR Δ Tyr was measured and the dependence of the rupture force with the loading rate was
307 plotted in the DFS graph in **Figure 5B**. A non-linear dependency of the rupture force with the
308 loading rate was again observed and the FNdY model was used to fit the data. We extracted an
309 equilibrium force F_{eq} of 32 ± 14 pN, a binding equilibrium free energy ΔG_{bu} of -4.7 ± 3.4 kcal
310 mol⁻¹ and a receptor-ligand half-residence time, $\tau_{0.5}$ of 0.5 ms. The calculated ΔG_{bu} corresponds
311 to a dissociation constant K_d of ≈ 20 mM and corresponds to a surprisingly low-affinity, in
312 contrast to the high-affinity binding of C5aR^{WT}. To further increase the accuracy of the
313 extracted parameters, we also recorded specific binding events at lower LRs by oscillating the

314 cantilever at frequencies of 1-10 Hz (**Figure 5C**). The measured forces over the low LR regime
315 (10^2 - 10^5 pN·s⁻¹) align well with binding forces obtained at higher LR (10^5 - 10^7 pN·s⁻¹). The
316 superimposition of the rupture forces obtained in the lower LR regime (10^2 - 10^5 pN·s⁻¹) to the
317 high LR makes it possible to better visualize the existence of a force plateau in the close-to-
318 equilibrium regime as predicted by the FNdY model (Friddle, Noy *et al.*, 2012). The fit of the
319 whole data set (low and high LR) gives very close values for the extracted parameters (**Figures**
320 **5B and C**).

321 **The rigid core of C5a has a low affinity for the C5aR binding site**

322 As the binding of C5a to the C5aR ES alone fails to explain the high-affinity interaction, we also
323 explored the binding between the C5a rigid core and the C5aR BS (**Figures 5D-F**). To specifically
324 target the BS, we abolished the interactions that could be established with the ES site using two
325 different approaches: (i) injection of free PMX53 (**Figure 5D**) and (ii) using C5a des-Arg + PMX53
326 (**Figure 5E**). C5a des-Arg is an endogenous truncated C5a derivative lacking the R74 at its C-
327 terminal end, which is known to be crucial for the interaction with the ES (Cain, Coughlan *et al.*,
328 2001; Higginbottom, Cain *et al.*, 2005).

329 Fitting the DFS plots with the FNdY model revealed that the inner core of the C5a binds to C5aR
330 BS with free-energy values (ΔG_{bu}) of -3.9 kcal mol⁻¹ and -1.5 kcal mol⁻¹, depending on the
331 presence or absence of the R74 residue. The most energetically unfavored complex was
332 observed when the C5a des-Arg ligand was probed along with PMX53 injection ($\Delta G_{bu} \approx -1.5$ kcal
333 mol⁻¹). We also looked into the kinetics aspect of the C5a-BS interaction and quantified the
334 complex stability in terms of residence time. $\tau_{0.5}$ values of 0.2 and 0.5 ms were obtained for the
335 two conditions (**Figures 5D,E**). The most stable complex was the one formed by the C5a des-
336 Arg ligand probed in the presence of free PMX53 in solution ($\tau_{0.5} \approx 0.5$ ms). Since the exact
337 structural details of C5a interaction with its receptor have not been revealed experimentally
338 yet, it is difficult to engineer specific mutants that would completely abrogate the interaction
339 at the ES. As, in both cases the interactions to the ES are abolished by PMX53, the high-affinity
340 antagonist, we only probed the interaction to the BS site and combine the results obtained
341 above (**Figure 5F**). Fitting with the FNdY model gave an equilibrium force F_{eq} of 23 ± 9 pN and
342 a binding equilibrium free energy ΔG_{bu} of -2.5 ± 1.9 kcal mol⁻¹. The calculated ΔG_{bu} corresponds
343 to a very low dissociation constant K_d of ≈ 0.8 M. To further increase the accuracy of the
344 extracted parameters, we also explored the close-to-equilibrium regime of the binding of C5a

345 to the C5aR BS (**Figure 5F**). We obtained very close F_{eq} values (23 ± 3 pN for the whole set vs 23
346 ± 9 pN for only the high LR range). The residence time and binding free-energy also remain
347 unchanged.

348 The two-fold difference in ΔG_{bu} between C5a binding at the ES and the BS, together with the
349 higher affinity for the ES, suggest that the interactions at the ES largely dominate the binding
350 of C5a to C5aR, while still weak when measured individually. Nevertheless, we hypothesize the
351 binding to multiple intramolecular sites, such as the ES and BS, stabilizes the overall binding,
352 increasing the ligand residence time and therefore acting as a kinetic trap with the purpose of
353 raising the local binding concentration.

354 **High-affinity C5a binding results from positive allostery between ES and BS**

355 In the light of the results obtained above, we further analyzed the functional activation of the
356 C5aR^{WT} and C5aR^{D282A} mutant exposed to C5a and C5a des-Arg (**Figures 6A,B and S5**). We
357 observed for the C5aR^{D282A} mutant a strong reduction on the G_i-protein activation in response
358 to increased concentration of C5a (**Figure 6B**), revealing that in addition to its important role in
359 the ligand affinity, this residue also modulates C5aR functional state. Otherwise, functional
360 assays performed with the truncated C5a des-Arg suggested that the loss of the interactions
361 between C5aR-D282 and C5a-R74 only slightly affect the normal C5aR function (**Figure 6A**).

362 Next, we wanted to know to what extent the binding of the C5a ligand to the ES influences the
363 binding in the overall C5a-C5aR complex (**Figures 6C-F**). We tested the influence of the C5a-R74
364 residue (using C5a des-Arg mutant) and the C5aR-D282 mutation. For the C5a-C5aR interaction
365 (probed in the high LR range) we obtain very similar results as previously determined (**Figure**
366 **3**): an equilibrium force F_{eq} of 54 ± 12 pN, a binding equilibrium free energy ΔG_{bu} of -14.8 ± 3.5
367 kcal mol⁻¹ and a dissociation constant K_d of ≈ 1 nM. Deletion of the R74 residue in the C terminal
368 segment or mutation of the D282 residue in the C5aR lead to strong effect with a three-fold
369 drop of the ΔG_{bu} , in the low-affinity regime (**Figures 6D-F**). These results corroborated our
370 previous observation that each sub-site (ES or BS) taken individually interacts with low-affinity
371 in the molar or millimolar range, alluding to a possible cooperative action between both sites
372 in the overall binding mechanism. To address this, we performed a two-sample t-test
373 distribution with the hypothesis that the ΔG_{bu} of the full ligand is larger than the sum of the
374 ΔG_{bu} of each binding sites (ΔG_{bu} (BS+ES)). However, although it is still difficult or impossible to
375 develop general models for multiple bonds within a molecular assembly, we can nevertheless

376 assume that a maximum ΔG_{bu} would be observed for bonds failing cooperatively when loaded
377 in parallel, that would mean $\Delta G_{bu}(BS+ES) = \Delta G_{bu}(BS) + \Delta G_{bu}(ES) = -7.2 \pm 2.0 \text{ kcal mol}^{-1}$. The t-test
378 confirms (p-value=0.964) that the full-ligand binding free-energy ($\Delta G_{bu}(C5a)$) is significantly
379 higher than the sum of the binding free-energy of both sites measured individually (ΔG_{bu}
380 (BS+ES)), confirming a positive allosteric interactions between the two orthosteric binding sites,
381 establishing the full interaction with the C5a. Our AFM experiments further suggest that the
382 interaction between C5a-R74 and C5aR-D282 plays a pivotal role into this cooperative
383 mechanism. Indeed, the single point mutation into the C5aR (D282A) or truncated C5a des-Arg
384 is sufficient to completely abolish this high affinity interaction state (**Figure 6D-F**).
385

386 Discussion

387 GPCRs represent the largest human membrane protein family, having overall more than 800
388 members, and constitute a “control panel” of the cell (Latorraca, Venkatakrishnan *et al.*, 2017).
389 As predominant actors in cells, GPCRs are intensively studied as drug targets, where in
390 particular C5aR has long been suggested as a new promising anti-inflammatory target. Intensive
391 research on C5aR has led to the design of several antagonists including the peptide antagonist
392 PMX53 and several non-peptide antagonists such as NDT9513727 and avacopan. PMX53 is a
393 potent orthosteric antagonist with insurmountable action (Seow, Lim *et al.*, 2016), although its
394 peptidic nature has limited its clinical development (Klos, Wende *et al.*, 2013). Among the
395 current available non-peptide antagonists, only avacopan showed sufficient therapeutic
396 efficacy to advance into late-stage clinical trials (Bekker, Dairaghi *et al.*, 2016; Jayne, Bruchfeld
397 *et al.*, 2017). Recent structural studies on C5aR revealed that the non-peptide antagonists
398 (including avacopan and NDT9513727) are actually allosteric modulators with highly reversible
399 action (Liu, Kim *et al.*, 2018; Robertson, Rappas *et al.*, 2018). Further development of
400 orthosteric non-peptide antagonists could be preferred as they may exhibit an insurmountable
401 action similar to PMX53. Corroborated with previous studies revealing the structural basis for
402 the action of PMX53 (Liu, Kim *et al.*, 2018), our kinetic and thermodynamic insights of PMX53
403 binding to the receptor effector site confirmed by MD and SMD simulations, shed more light
404 into the activation mechanism of C5aR and the amino acid residues involved, which could be
405 useful for future drug discovery studies.

406 Atomic-resolution structures are now available for more than 50 different GPCRs and over 250
407 of their complexes with different ligands (Shimada, Ueda *et al.*, 2018). Crystal structures of
408 C5aR in complex with NDT9513727, PMX53 and avacopan have recently been reported (Liu,
409 Kim *et al.*, 2018; Robertson, Rappas *et al.*, 2018). However, despite the dramatic progress
410 during the last decade in deciphering the structural insights of C5aR activation mechanism,
411 none of those recent structural studies have been performed with the C5a ligand. In addition,
412 the function of GPCRs depends critically on their ability to change shape, transitioning among
413 distinct conformations, while crystal structures only depict discrete snapshots of a dynamic
414 process. Although for some GPCRs several small drug candidates have been developed using
415 solely structure-based drug design methodologies (Rodríguez, Ranganathan *et al.*, 2015), a full
416 understanding of the dynamic properties of GPCRs is preferred and probably essential for
417 future drug development, especially for those with large peptide or protein ligands. Here, we

418 introduced an FD-based AFM approach and a new experimental strategy to extract the kinetic
419 and thermodynamic parameters governing large-ligand binding to multiple orthosteric binding
420 sites of receptors in physiologically relevant conditions. We also used MD and SMD simulations
421 as a powerful complementary method to our experimental approach, allowing us to gain new
422 insights into the binding pocket structure and the important residues involved in the specific
423 recognition of ligands.

424 Our study addressed the complex binding process of a large ligand to a GPCR. C5a, a 74-aa
425 glycoprotein binds to C5aR through two distinct and physically separated binding sites, namely
426 the effector and binding site (Siciliano, Rollins *et al.*, 1994). While the existence of the two-site
427 binding motif has been previously reported (Siciliano, Rollins *et al.*, 1994), the functional
428 relationship between the two sites was missing until now. Our method enabled, for the first
429 time, to probe multiple ligand binding sites at the sub-site level in order to study their
430 respective contribution to the overall binding. We demonstrated that both orthosteric ligand
431 binding sites interact with the ligand with a low affinity when working independently.
432 Interestingly, when acting in a concerted manner, the interaction rises into a high-affinity
433 interaction, suggesting a cooperativity between both orthosteric binding sites (**Figure 6G**). This
434 cooperativity effect resulting from multiple binding site is supported by the theory that predicts
435 (Williams, 2003; Sulchek, Friddle *et al.*, 2006) an enormous increase of the time scale needed
436 for ligand dissociation upon cooperative binding.

437 Through our experimental approach combining AFM and simulations, we were able to capture
438 the “cryptic” binding pockets of C5a into C5aR and to reconstruct the binding free-energy
439 landscape for this complex binding mechanism. The importance of the D282 at the extracellular
440 face of TM7 was also put in evidence. Although already predicted to form an important
441 interaction with R74 of C5a, this interaction remained so far a mystery since some D282
442 mutants were showed to be relatively unresponsive to C5a but sensitive to C5a des-Arg and
443 analogs (Cain, Coughlan *et al.*, 2001; Cain, Higginbottom *et al.*, 2003). More recently, it has
444 been shown that the truncated C5a des-Arg bind C5a in an entirely different orientation, which
445 could be an intermediate state. For the first time, we decipher that this interaction is only
446 established for the full C5a ligand and that the ligand-binding in its high-affinity state involved
447 the concerted action of both the binding and effector sites. We envision that this better
448 understanding of the dynamic binding of C5a to C5aR in physiologically relevant conditions will
449 open new avenues in the rational design of finely tuned drugs. Ultimately, this approach will

450 serve as a valuable tool to further develop and test agonists and antagonists to other GPCRs
451 with macromolecular ligands.
452

453 **Materials and methods**

454 **C5aR^{WT} expression, purification and Western Blot**

455 The wild type C5aR and mutant were expressed in mammalian HEK-293S GnT1⁻ cells (ATCC)
456 using the BacMam method (Dukkipati, Park *et al.*, 2008). All constructs were cloned into a
457 vector engineered from pFastBac (Invitrogen) by introducing a CMV promoter (Dukkipati, Park
458 *et al.*, 2008). All protein was expressed with a C-terminal His₈ tag and an N-terminal Flag tag.
459 Baculovirus was generated by the Bac-to-Bac method (Invitrogen). The mammalian HEK-293S
460 GnT1⁻ cells were cultured in suspension at 37°C and under 5% CO₂. The cells were infected at a
461 density of 4x10⁶ ml⁻¹ with baculovirus and then harvested after 24h.

462 To purify the protein, infected cells were lysed in buffer containing 10 mM Tris pH 7.5, 150 µg
463 ml⁻¹ benzamidine, 0.2 µg·ml⁻¹ leupeptin and 2 mg·ml⁻¹ iodoacetamide. The cell membrane was
464 collected by centrifugation at 24,000 g for 40 min at 4°C and then solubilized in buffer
465 containing 20 mM HEPES pH 7.5, 750 mM NaCl, 1% dodecyl maltoside (DDM), 0.2% cholesterol
466 hemisuccinate (CHS), 0.2% sodium cholate, 20% glycerol, 150 µg·ml⁻¹ benzamidine, 0.2 µg·ml⁻¹
467 leupeptin, 2 mg·ml⁻¹ iodoacetamide and 5 U/l Salt Active Nuclease (Sigma) for 1 h at 4 °C. The
468 supernatant was collected after centrifugation at 24,000 g for 40 min, and incubated with Ni-
469 NTA agarose resin (Clontech) in batch for overnight at 4°C. The resin was washed three times
470 in batch with buffer comprised of 20 mM HEPES pH 7.5, 500 mM NaCl, 0.1% DDM, 0.02% CHS,
471 150 µg·ml⁻¹ benzamidine, 0.2 µg·ml⁻¹ leupeptin and 20 mM imidazole, and then transferred to
472 a gravity column. After extensive washing, the protein was eluted in wash buffer with 400 mM
473 imidazole and 2 mM CaCl₂. The eluted protein was loaded onto anti-Flag M1 antibody affinity
474 resin. After washing with buffer containing 20 mM HEPES pH 7.5, 100 mM NaCl, 0.1% DDM,
475 0.02% CHS, 2 mM CaCl₂, the protein was eluted with buffer containing 20 mM HEPES, pH 7.5,
476 100 mM NaCl, 0.1% DDM, 0.02% CHS, 200 µg·ml⁻¹ Flag peptide and 5 mM EDTA. The protein
477 was further purified by size exclusion chromatography with buffer containing 20 mM HEPES pH
478 7.5, 100 mM NaCl, 0.05% DDM, 0.01% CHS.

479 Mouse anti-FLAG M1 antibody and mouse anti-Sulfo tyrosine antibody (Sigma) were used to
480 detect the purified wild type C5aR and C5aRΔTyr with Y11F and F14F mutations respectively in
481 the western blotting assays.

482 **C5aR mutants expression, purification and ³⁵S-GTPγS binding assay**

483 Mutant variants (D282A, D282N and R175V/Y258V) were generated based on the wtC5aR
484 construct and fully sequenced. Mutant variants were expressed following the same method as

485 for wtC5aR except for some modifications. HEK-293S cells expressing each mutant were
486 pelleted by centrifugation and resuspended in 20 ml buffer containing 20 mM HEPES pH 7.5,
487 100 mM NaCl, 0.2 µg/ml leupeptin and 150 µg/ml benzamidine. After 20 min incubation at 25
488 °C, 20 ml 2X solubilization buffer containing 20 mM HEPES pH 7.5, 100 mM NaCl, 1% dodecyl-
489 maltoside (DDM), 0.2% cholesterol hemisuccinate (CHS), 20% glycerol, 0.2 µg/ml leupeptin,
490 150 µg/ml benzamidine and 5 U Salt Active Nuclease (Sigma) was added. Cell membranes were
491 solubilized for 1.5 hour at 4 °C. The supernatant was collected by centrifugation at 24,000 g
492 for 30 min at 4 °C, and then incubated with anti-Flag M2 antibody affinity resin (Sigma) for 1.5
493 hour at 4°C. After washing the resin with buffer containing 20 mM HEPES pH 7.5, 100 mM NaCl,
494 0.1% DDM, 0.02% CHS, 0.2 µg/ml leupeptin, and 150 µg/ml benzamidine, the protein was
495 eluted from M2 resin using the buffer containing 20 mM HEPES pH 7.5, 100 mM NaCl, 0.1%
496 DDM, 0.02% CHS and 200 µg/ml Flag peptide (GL Biochem). The protein was further purified
497 by size exclusion chromatography with the same buffer as for wtC5aR.

498 For the ³⁵S-GTPγS binding assays, the membrane of HEK293S GnT1⁻ cells expressing wtC5aR
499 (~200 µg/ml) or mutant variants was incubated with 200 nM purified G_i protein for 30 minutes
500 on ice in buffer containing 20 mM HEPES pH 7.5, 100 mM NaCl, 5mM MgCl₂, 3 µg/ml BSA,
501 0.1µM TCEP, and 5µM GDP to get the receptor and G_i complex. Next, 25 µL aliquots of the pre-
502 formed complex were mixed with 225 µL reaction buffer containing 20 mM HEPES, pH 7.5, 100
503 mM NaCl, 5mM MgCl₂, 3 µg/ml BSA, 0.1µM TCEP, 1µM GDP, 35 pM ³⁵S-GTPγS (Perkin Elmer)
504 and C5a (R&D Systems). After additional 15 min incubation at 25 °C, the reaction was
505 terminated by adding 5 ml of cold wash buffer containing 20 mM HEPES pH 7.5, 100 mM NaCl
506 and 5mM MgCl₂, and filtering through glass fiber filters (Millipore Sigma). After washing the
507 filters twice with 5 ml cold wash buffer, the filters were incubated with 5 ml of CytoScint liquid
508 scintillation cocktail (MP Biomedicals). The radiation of bound ³⁵S-GTPγS was measured on a
509 Beckman LS6500 scintillation counter to determine the binding of ³⁵S-GTPγS to G_i induced by
510 C5aR activation. The data analysis was performed using GraphPad Prism 6 (GraphPad
511 Software). Results are shown as mean ± s.d. from 3 independent experiments.

512 C5aR liposomes preparation

513 C5aR liposomes were prepared according to previously published method(Pfreunds Schuh,
514 Alsteens *et al.*, 2015). The empty liposomes were prepared from a mix of DOPC (1,2-Dioleoyl-
515 sn-glycero-3-phosphocholine) (Avanti lipids) and CHS (Sigma). DOPC and CHS were dissolved in
516 chloroform at a 10:1 (wt:wt) ratio, then mixed and dried. The well-mixed DOPC/CHS was re-

517 suspended and dissolved in buffer containing 20 mM HEPES pH 7.5, 100 mM NaCl, 1%
518 octylglucoside (OG) under sonication on ice. Aliquots of dissolved DOPC/CHS lipids were flash-
519 frozen in liquid nitrogen and stored at -80 °C. To reconstitute C5aR in liposomes, protein and
520 lipids were mixed at a 10 µM:1mM final ratio, and incubated on ice for 2h. The detergent was
521 removed by biobeads (Bio-rad) and extensive dialysis.

522 **C5aR preparation for AFM measurements**

523 The reconstituted C5aR sample solution (either wt-C5aR or mutants) was 20-fold diluted in
524 fusion buffer solution (20 mM HEPES, 300 mM NaCl, 25 mM MgCl₂) and adsorbed on freshly
525 cleaved mica for 15 minutes. After rinsing with imaging buffer (20 mM HEPES and 300 mM
526 NaCl) the sample was transferred to the AFM.

527 **Functionalization of AFM tips**

528 Rectangular Si₃N₄ AFM cantilevers with silicon tips (BioLever mini, Bruker) were first cleaned
529 with chloroform for 10 min, rinsed with ethanol, N₂ dried and then cleaned for 15 min in an
530 ultraviolet radiation and ozone cleaner (UV-O, Jetlight, CA, USA). For the
531 aminofunctionalization, the cantilevers were immersed in an ethanolamine solution (3.3 g
532 ethanolamine in 6.6 ml DMSO) overnight and then rinsed in DMSO (3 x 1 min) and ethanol (3 x
533 1 min), followed by N₂ drying (Wildling, Unterauer *et al.*, 2011). This was followed by the N-
534 hydroxysuccinimide (NHS)-PEG₂₇-acetal linker attachment. A 1 mg portion of the NHS-PEG₂₇-
535 acetal linker (JKU, Linz, Austria) was diluted in 0.5 ml chloroform with 30 µl triethylamine and
536 the cantilevers were immersed in this solution for 2 h. After 3 rinsing steps of 10 min in
537 chloroform and N₂ drying, the cantilevers were immersed in a 1% citric acid solution for 10
538 minutes, rinsed with pure water (3 x 5 min) and dried with N₂ once more. Tris-NTA-derivatized
539 AFM cantilevers were obtained by pipetting 100 µl of a 100 µM tris-nitrilotriacetic amine
540 trifluoroacetate (Toronto Research Chemicals, Canada) (tris-NTA) solution onto the cantilevers,
541 followed by the addition of 2 µl of a freshly prepared 1 M NaCNBH₃ solution. The cantilevers
542 were incubated for 1 h, then 5 µl of a 1 M ethanolamine solution pH 8.0 were added for 10
543 minutes to quench the reaction. Tris-NTA cantilevers were further used to obtain C5a- or C5a
544 des-Arg-derivatized tips. For this purpose, 100 µl of a 1 µM C5a or C5a des-Arg protein solution
545 was premixed with 5 µl NiCl₂ 5 mM and the mixture was pipetted onto the tris-NTA cantilevers.
546 After 2h of incubation time, the cantilevers were washed in HEPES buffer 3 x 5 minutes.
547 To functionalize AFM cantilevers with the PMX53 antagonist (Ace-Phe-[(Orn)-Pro-{D-Cha}-Trp-
548 Arg]), aminofunctionalized cantilevers were immersed for 2 h in a solution prepared by mixing

549 1 mg of NHS-PEG₂₇-maleimide(Wildling, Unterauer *et al.*, 2011) (JKU, Linz, Austria) dissolved in
550 0.5 ml of chloroform with 30 μ l of triethylamine, then washed with chloroform and dried with
551 N₂. The cystein bearing peptide Cys-Gly₃-Phe-{{Orn}-Pro-{D-Cha}-Trp-Arg] (PMX53-Gly₃-Cys)
552 was obtained from GL Biochem (Shanghai). A 100 μ l solution of Cys-Gly₃-PMX53 1 mM was
553 premixed with 2 μ l of EDTA (100 mM, pH 7.5), 5 μ l of HEPES (1 M, pH 7.5), 2 μ l of TCEP
554 hydrochloride (100 mM) and 2 μ l of HEPES (1 M, pH 9.6), then pipetted over the AFM
555 cantilevers. After 3 h of reaction, cantilevers were washed with PBS 3 x 5 minutes.

556 **FD-based AFM**

557 AFM experiments were performed with a Multimode 8 AFM equipped with a Nanoscope V
558 controller (Bruker, Santa Barbara, CA, USA) operated in "PeakForce Tapping QNM mode". All
559 measurements were carried out in imaging buffer at room temperature ($\approx 24^{\circ}\text{C}$). For the high-
560 resolution characterization of C5aR topographical features, triangular Si₃N₄ cantilevers
561 (Scanasyst-Fluid+, Bruker) with a sharpened tetrahedral silicon tip of ≈ 2 nm radius, nominal
562 spring constants of 0.35 N/m and resonance frequency in liquid of ≈ 75 kHz were used.
563 Multiparametric FD-based AFM measurements with derivatized tips were carried out using
564 BioLever mini cantilevers (Bruker, Santa Barbara) having nominal spring constants of 0.1 N/m
565 and resonance frequency in liquid of ≈ 25 kHz. The spring constant was calibrated at the end of
566 each experiment for all cantilevers used in this study using the thermal noise method(Butt and
567 Jaschke, 1995).

568 In FD-based AFM measurements, the AFM cantilever is oscillated in a sinusoidal manner well
569 below its resonance frequency, while the sample surface is contoured pixel-by-pixel. For each
570 approach-retraction cycle of the oscillating cantilever, a force-distance curve is recorded.
571 Multiparametric FD-based AFM height, Young's modulus and adhesion maps are then obtained
572 from a pixel-by-pixel reconstruction of the acquired data. Overview FD-based AFM maps were
573 acquired by scanning the sample at 1 Hz and a resolution of 512 x 512 pixels, using a force
574 setpoint of ≈ 150 pN, a 2 kHz oscillation frequency and a peak-to-peak oscillation amplitude of
575 100 nm. Adhesion maps were recorded using a scan rate of 0.2 Hz and 256 x 256 pixels. The
576 functionalized AFM cantilever was oscillated at 0.25 kHz with peak-to-peak oscillation
577 amplitudes of 100 nm. To vertically oscillate the AFM tip at 1–10 Hz, FD-based AFM was
578 conducted in the ramp mode with a force setpoint of 200 pN, an approach velocity of 1 $\mu\text{m}\cdot\text{s}^{-1}$,
579 retraction velocities of 0.5-2 $\mu\text{m}\cdot\text{s}^{-1}$, a ramp size of 150 nm and no surface delay.

580

581 Control Experiments

582 Several control experiments were designed to ensure that the measured interactions were
583 indeed specific and the functionalization of the AFM tip successful. Adhesion maps of C5aR
584 reconstituted samples were imaged with unmodified or ethanolamine-coated AFM tips (**Figure**
585 **S1A, D**). We also tested C5a ligand binding before and after injection of free C5a on the sample
586 surface (**Figure S1C,D**). In another approach, tris-NTA binding to C-terminal of C5aR was tested
587 in the presence of 10 mM EDTA (**Figure S1E,F**).

588 Data analysis

589 Raw images were analyzed using the Gwyddion 2.5 free software. Force-distance curves were
590 analyzed using the Nanoscope Analysis 1.80 Software (Bruker). Individual force-distance curves
591 corresponding to specific adhesion events were extracted and further analyzed using the
592 OriginLab software. Adhesion forces were calculated as the minimum force in the retraction
593 segment of the force-distance curve and the loading rate was measured as the slope of the
594 force versus time curve just before rupture. The noise level was calculated by doing a linear fit
595 of the retraction part of the force distance curve and calculating the standard deviation. We
596 obtained noise values between 10-15 pN and set a threshold for the specific unbinding events
597 above 25 pN. Dynamic Force Spectroscopy (DFS) graphs were obtained by plotting the loading-
598 rate dependence of the adhesion force and a nonlinear iterative fitting algorithm (Levenberg-
599 Marquardt) was used with the FNdY model to extract kinetic and thermodynamic parameters
600 of the interactions. The fits were plotted along with the 99% confidence intervals and 99%
601 prediction intervals.

602 The robustness of the FNdY fit was tested for the dataset in Figure 3H using MATLAB. We
603 maintained one of the three fit parameters (x_{β} , F_{eq} , k_{off}) constant and varied the two others
604 parameters (**Figure S6**). The robustness of a fit is usually evaluated in terms of R^2 values, but R^2
605 is not an optimal choice in a nonlinear regime as the total sum-of-squares (TSS) is not equal to
606 the regression sum-of-squares (REGSS) plus the residual sum-of-squares (RSS), as is the case in
607 linear regression. To circumvent the issue of the low performance of R^2 and its
608 inappropriateness for nonlinear data analysis, we calculated the sum of the squared differences
609 between the experimental data values and the FNdY fits using the tested parameters. This
610 performance value, *i.e.* the sum of the squared differences, shows how far the data points are
611 from the regression line on average, so low values are indicators of good fit parameters, while
612 high values indicate a poor fit parameter. 2D color maps were reconstructed with color scales

613 showing log-values of the sum of the squared differences between the experimental data
614 values and the FNdY fits with the tested parameters. Minimum values (dark blue) are indicators
615 of the best parameters, while maximum values (dark red) correspond to regions where the fit
616 is poor.

617 **Molecular Dynamics simulation system setup**

618 The dual antagonist-bound C5aR structure complexed with PMX53 and avacopan in the
619 orthosteric and allosteric sites, respectively, solved by Liu et al. [PDB ID: 6C1R] was used for
620 setup of the simulation systems. All atoms other than those of C5aR and PMX53 (avacopan,
621 solvent, lipids, etc.) were removed along with the engineered N-terminal cytochrome *b*₂₆₂ RIL
622 (BRIL). All non-terminal missing regions (234-236, 308-312) were modeled using MODELLER
623 v9.13 via the *Model Loops/ Refine Structure* module available in UCSF Chimera (Pettersen,
624 Goddard *et al.*, 2004) . A total of 500 structures with the missing loop regions were modeled
625 and the one with the best zDOPE score was selected for preparation of the system for molecular
626 dynamics (MD) simulations.

627 For the PMX53-C5aR double-mutant system, the R175V and Y258V mutations were introduced
628 into the WT-C5aR-PMX53 system using the *Rotamers* module available in USCF Chimera. The
629 N- and C-termini of C5aR were acetylated and amidated, respectively. The C5aR-PMX53
630 complex was then embedded in a lipid bilayer comprising 164 POPC (1-palmitoyl-2-oleoyl-*sn*-
631 glycerol-3-phosphocholine) molecules (82 each on the upper and lower layers) using the
632 CHARMM-GUI server. The receptor-antagonist-lipid system was then solvated with 27000
633 TIP3P water molecules, and NaCl at a concentration of 150 mM was added. The final
634 dimensions of the system were $\sim 79.1 \text{ \AA} \times 79.1 \text{ \AA} \times 170 \text{ \AA}$ comprising $\sim 108,000$ atoms.
635 CHARMM36 force field(Klada, Venable *et al.*, 2010) parameters were used to model protein,
636 lipids, ions, and water molecules. For PMX53, force field parameters were assigned by analogy
637 using CHARMM general force field (CGenFF) via the ParamChem server(Ghosh, Marru *et al.*,
638 2011).

639 GROMACS v5.1.2 (Ref.(Abraham, Murtola *et al.*, 2015)) was used for performing all the
640 simulations. Short-range non-bonded interactions were calculated with a 1.2 nm cut-off, and
641 the particle mesh Ewald (PME) algorithm(Darden, York *et al.*, 1993) was employed for
642 calculation of long-range electrostatics. LINCS(Hess, Bekker *et al.*, 1997) algorithm was used to
643 constraint all H-atom containing bonds. The system was first energy minimization using
644 steepest decent algorithm. Subsequently, the system was equilibrated in a stepwise manner,

645 first in an NVT ensemble (three steps, 50ps each with 1fs time step) maintained at 310 K by
646 Berendsen coupling. The system was then equilibrated in an NPT ensemble (three steps, 100ps
647 each with 2fs time step) maintained at 310 K and 1.0 bar using Berendsen coupling. The
648 harmonic position restraints applied to the heavy atoms of C5aR, PMX53 and POPC were
649 reduced gradually at each of the six equilibration steps to ensure thorough equilibration of the
650 system. Following equilibration, all restraints were removed and production runs were carried
651 out by maintaining the temperature (310 K) and pressure (1.0 bar) with the help of Nosé-
652 Hoover thermostat and Parrinello-Rahman barostat, respectively. Pressure coupling was
653 carried out semi-isotropically for NPT equilibration and production runs. Finally, a production
654 run of 300 ns was carried out.

655 **Center-of-Mass (COM) Pulling and Umbrella Sampling Simulations**

656 The resultant configuration of the 300 ns production run was used for performing the COM
657 pulling simulations. The final configuration was equilibrated for 100ps in an NPT ensemble.
658 Subsequently, with positional restraints placed only on the C5aR molecule in the z-direction,
659 the bound PMX53 cyclic peptide was pulled away from C5aR binding pocket. The pulling
660 simulation was carried out over 1 ns along the z-axis with a pull rate of 0.005 nm ps⁻¹ and spring
661 constant of 1000 kJ mol⁻¹ nm⁻². Configurations were extracted from the pulling simulations at
662 0.1 nm intervals until the C5aR-PMX53 COM-COM distance was 3.0 Å, and at 0.2 nm intervals
663 thereafter until the final COM-COM distance was 6.0 Å. In total, 36 configurations were
664 generated to serve as umbrella sampling windows. Each of the 36 umbrella sampling windows
665 were equilibrated for 100 ps in an NPT ensemble followed by a 40 ns production run while
666 applying a 1000 kJ mol⁻¹ nm⁻² force constant along the z-axis on the PMX53 molecule. Finally,
667 the free energy profile of transferring PMX53 from its bound state to an unbound state was
668 calculated using the weighted histogram analysis (WHAM) as implemented in GROMACS v5.1.2.
669 Bootstrap analysis was used for estimation of statistical errors.

670 **Analysis of non-covalent interactions**

671 The various non-covalent interactions were estimated using built-in GROMACS tools and in-
672 house Perl scripts. Hydrogen bonds were estimated using the gmx hbond tool using default
673 criteria. Cation- π and salt-bridge interactions were defined based on the distance criteria
674 described elsewhere.

675

676

677 **Author contributions**

678 # A.C.D, H.L and R.N.V.K.D contributed equally to this work.

679

680 A.C.D. and M.K. set up and performed the AFM experiments. D.A. and A.C.D. coanalyzed the
681 experimental and performed calculations. C.Z. and H.L. provided some of the ligands and
682 cloned, purified and reconstituted C5aR. H.F. and R.N.V.K.D. set up and performed the
683 MD/SMD simulations and analysis. All authors wrote the paper.

684

685 **Acknowledgements**

686 This work was supported by the Fonds National de la Recherche Scientifique (F.R.S.-FNRS grant
687 numbers: PDR T.0090.15 to D. Alsteens), the Research Department of the Communauté
688 française de Belgique (Concerted Research Action), the Université catholique de Louvain (Fonds
689 Spéciaux de Recherche), the 'MOVE-IN Louvain' Incoming post-doc Fellowship programme to
690 A. Dumitru and the National Institute of Health of United States (1R35GM128641-01 to C.
691 Zhang.). D. Alsteens. is Research Associate at the FNRS. H. Fan gratefully acknowledges financial
692 support from Biomedical Research Council of A*STAR. This work was also supported by funding
693 from National Institute of Health. The computational work was performed on resources of the
694 National Supercomputing Centre, Singapore (<https://www.nsc.sg>). The authors thank M.
695 Mathelie-Guinlet (Université catholique de Louvain) and A. Vilquin (École supérieure de
696 physique et de chimie industrielles de la ville de Paris) for the support with MATLAB routine
697 coding.

698 **References**

- 699 Abraham, M. J., T. Murtola, R. Schulz, S. Páll, J. C. Smith, B. Hess and E. Lindahl (2015).
700 GROMACS: High performance molecular simulations through multi-level parallelism from
701 laptops to supercomputers. *SoftwareX* **1**: 19-25.
- 702 Alsteens, D., M. Pfreunds Schuh, C. Zhang, P. M. Spoerri, S. R. Coughlin, B. K. Kobilka and D. J.
703 Müller (2015). Imaging G protein-coupled receptors while quantifying their ligand-binding
704 free-energy landscape. *Nat. Meth.* **12**(9): 845-851.
- 705 Alsteens, D., M. Pfreunds Schuh, C. Zhang, P. M. Spoerri, S. R. Coughlin, B. K. Kobilka and D. J.
706 Müller (2015). Imaging G protein-coupled receptors while quantifying their ligand-binding
707 free-energy landscape. *Nature Methods* **12**(9): 845-851.
- 708 Bekker, P., D. Dairaghi, L. Seitz, M. Leleti, Y. Wang, L. Ertl, T. Baumgart, S. Shugarts, L. Lohr, T.
709 Dang, S. Miao, Y. Zeng, P. Fan, P. Zhang, D. Johnson, J. Powers, J. Jaen, I. Charo and T. J. Schall
710 (2016). Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a
711 Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on
712 Preclinical Evaluation and Randomized Phase 1 Clinical Study. *PLOS ONE* **11**(10): e0164646.
- 713 Butt, H. J. and M. Jaschke (1995). Calculation of thermal noise in atomic force microscopy.
714 *Nanotechnology* **6**(1): 1.
- 715 Cain, S. A., T. Coughlan and P. N. Monk (2001). Mapping the Ligand-Binding Site on the C5a
716 Receptor: Arginine74 of C5a Contacts Aspartate282 of the C5a Receptor. *Biochemistry* **40**(46):
717 14047-14052.
- 718 Cain, S. A., A. Higginbottom and P. N. Monk (2003). Characterisation of C5a receptor agonists
719 from phage display libraries. *Biochemical Pharmacology* **66**(9): 1833-1840.
- 720 Darden, T., D. York and L. Pedersen (1993). Particle mesh Ewald: An $N \cdot \log(N)$ method for
721 Ewald sums in large systems. *The Journal of chemical physics* **98**(12): 10089-10092.
- 722 Dufrene, Y. F., D. Martinez-Martin, I. Medalsy, D. Alsteens and D. J. Müller (2013).
723 Multiparametric imaging of biological systems by force-distance curve-based AFM. *Nat. Meth.*
724 **10**(9): 847-854.
- 725 Dufrene, Y. F., D. Martinez-Martin, I. Medalsy, D. Alsteens and D. J. Müller (2013).
726 Multiparametric imaging of biological systems by force-distance curve-based AFM. *Nature*
727 *Methods* **10**(9): 847-854.
- 728 Dukkupati, A., H. H. Park, D. Waghay, S. Fischer and K. C. Garcia (2008). BacMam system for
729 high-level expression of recombinant soluble and membrane glycoproteins for structural
730 studies. *Protein Expression and Purification* **62**(2): 160-170.
- 731 Dumitru, A. C., L. Conrard, C. Lo Giudice, P. Henriët, M. Veiga-da-Cunha, S. Derclaye, D. Tyteca
732 and D. Alsteens (2018). High-resolution mapping and recognition of lipid domains using AFM
733 with toxin-derivatized probes. *Chemical Communications* **54**(50): 6903-6906.
- 734 Dumitru, A. C., M. A. Poncin, L. Conrard, Y. F. Dufrêne, D. Tyteca and D. Alsteens (2018).
735 Nanoscale membrane architecture of healthy and pathological red blood cells. *Nanoscale*
736 *Horizons* **3**(3): 293-304.


- 737 Dumitru, A. C., M. A. Poncin, L. Conrard, Y. F. Dufrêne, D. Tyteca and D. Alsteens (2018).
738 Nanoscale membrane architecture of healthy and pathological red blood cells. *Nanoscale*
739 *Horiz.* **3**(3): 293-304.
- 740 Evans, E. and K. Ritchie (1997). Dynamic strength of molecular adhesion bonds. *Biophysical*
741 *Journal* **72**(4): 1541-1555.
- 742 Farzan, M., C. E. Schnitzler, N. Vasilieva, D. Leung, J. Kuhn, C. Gerard, N. P. Gerard and H. Choe
743 (2001). Sulfated Tyrosines Contribute to the Formation of the C5a Docking Site of the Human
744 C5a Anaphylatoxin Receptor. *The Journal of Experimental Medicine* **193**(9): 1059-1066.
- 745 Friddle, R. W., A. Noy and J. J. De Yoreo (2012). Interpreting the widespread nonlinear force
746 spectra of intermolecular bonds. *Proc. Natl. Acad. Sci. U. S. A.* **109**(34): 13573-13578.
- 747 Friddle, R. W., A. Noy and J. J. De Yoreo (2012). Interpreting the widespread nonlinear force
748 spectra of intermolecular bonds. *Proceedings of the National Academy of Sciences* **109**(34):
749 13573-13578.
- 750 Gerber, B. O., E. C. Meng, V. Dötsch, T. J. Baranski and H. R. Bourne (2001). An Activation
751 Switch in the Ligand Binding Pocket of the C5a Receptor. *Journal of Biological Chemistry*
752 **276**(5): 3394-3400.
- 753 Ghosh, J., S. Marru, N. Singh, K. Vanomesslaeghe, Y. Fan and S. Pamidighantam (2011).
754 Molecular parameter optimization gateway (ParamChem): workflow management through
755 TeraGrid ASTA. *Proceedings of the 2011 TeraGrid Conference: Extreme Digital Discovery,*
756 *ACM.*
- 757 Guo, R.-F. and P. A. Ward (2005). ROLE OF C5A IN INFLAMMATORY RESPONSES. *Annual Review*
758 *of Immunology* **23**(1): 821-852.
- 759 Hess, B., H. Bekker, H. J. Berendsen and J. G. Fraaije (1997). LINCS: a linear constraint solver
760 for molecular simulations. *Journal of computational chemistry* **18**(12): 1463-1472.
- 761 Higginbottom, A., S. A. Cain, T. M. Woodruff, L. M. Proctor, P. K. Madala, J. D. A. Tyndall, S. M.
762 Taylor, D. P. Fairlie and P. N. Monk (2005). Comparative Agonist/Antagonist Responses in
763 Mutant Human C5a Receptors Define the Ligand Binding Site. *Journal of Biological Chemistry*
764 **280**(18): 17831-17840.
- 765 Huber-Lang, M. S., J. V. Sarma, S. R. McGuire, K. T. Lu, V. A. Padgaonkar, E. M. Younkin, R. F.
766 Guo, C. H. Weber, E. R. Zuiderweg, F. S. Zetoune and P. A. Ward (2003). Structure-Function
767 Relationships of Human C5a and C5aR. *The Journal of Immunology* **170**(12): 6115-6124.
- 768 Jayne, D. R. W., A. N. Bruchfeld, L. Harper, M. Schaiyer, M. C. Venning, P. Hamilton, V. Burst, F.
769 Grundmann, M. Jadoul, I. Szombati, V. Tesař, M. Segelmark, A. Potarca, T. J. Schall and P.
770 Bekker (2017). Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated
771 Vasculitis. *Journal of the American Society of Nephrology* **28**(9): 2756-2767.
- 772 Klauda, J. B., R. M. Venable, J. A. Freites, J. W. O'Connor, D. J. Tobias, C. Mondragon-Ramirez,
773 I. Vorobyov, A. D. MacKerell Jr and R. W. Pastor (2010). Update of the CHARMM all-atom
774 additive force field for lipids: validation on six lipid types. *The Journal of Physical Chemistry B*
775 **114**(23): 7830-7843.
- 776 Klos, A., E. Wende, K. J. Wareham and P. N. Monk (2013). *International Union of Basic and*
777 *Clinical Pharmacology.* LXXXVII. Complement Peptide C5a, C4a, and C3a Receptors.
778 *Pharmacological Reviews* **65**(1): 500-543.

- 779 László, S., C. Miklós and H. László (2008). Dimerization and oligomerization of G-protein-
780 coupled receptors: debated structures with established and emerging functions. *Journal of*
781 *Endocrinology* **196**(3): 435.
- 782 Latorraca, N. R., A. J. Venkatakrishnan and R. O. Dror (2017). GPCR Dynamics: Structures in
783 Motion. *Chemical Reviews* **117**(1): 139-155.
- 784 Lemkul, J. A. and D. R. Bevan (2010). Assessing the Stability of Alzheimer's Amyloid Protofibrils
785 Using Molecular Dynamics. *The Journal of Physical Chemistry B* **114**(4): 1652-1660.
- 786 Liu, H., H. R. Kim, R. N. V. K. Deepak, L. Wang, K. Y. Chung, H. Fan, Z. Wei and C. Zhang (2018).
787 Orthosteric and allosteric action of the C5a receptor antagonists. *Nature Structural &*
788 *Molecular Biology* **25**(6): 472-481.
- 789 March, D. R., L. M. Proctor, M. J. Stoermer, R. Sbaglia, G. Abbenante, R. C. Reid, T. M.
790 Woodruff, K. Wadi, N. Paczkowski, J. D. A. Tyndall, S. M. Taylor and D. P. Fairlie (2004). Potent
791 Cyclic Antagonists of the Complement C5a Receptor on Human Polymorphonuclear
792 Leukocytes. Relationships between Structures and Activity. *Molecular Pharmacology* **65**(4):
793 868-879.
- 794 Monk, P. N., A.-M. Scola, P. Madala and D. P. Fairlie (2007). Function, structure and
795 therapeutic potential of complement C5a receptors. *British Journal of Pharmacology* **152**(4):
796 429-448.
- 797 Pettersen, E. F., T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C. Meng and T.
798 E. Ferrin (2004). UCSF Chimera—A visualization system for exploratory research and analysis.
799 *Journal of Computational Chemistry* **25**(13): 1605-1612.
- 800 Pfreundschuh, M., D. Alsteens, R. Wieneke, C. Zhang, S. R. Coughlin, R. Tampé, B. K. Kobilka
801 and D. J. Müller (2015). Identifying and quantifying two ligand-binding sites while imaging
802 native human membrane receptors by AFM. *Nat. Commun.* **6**: 8857.
- 803 Pfreundschuh, M., D. Alsteens, R. Wieneke, C. Zhang, S. R. Coughlin, R. Tampé, B. K. Kobilka
804 and D. J. Müller (2015). Identifying and quantifying two ligand-binding sites while imaging
805 native human membrane receptors by AFM. *Nature Communications* **6**: 8857.
- 806 Rigato, A., F. Rico, F. Eghiaian, M. Piel and S. Scheuring (2015). Atomic Force Microscopy
807 Mechanical Mapping of Micropatterned Cells Shows Adhesion Geometry-Dependent
808 Mechanical Response on Local and Global Scales. *ACS Nano* **9**(6): 5846-5856.
- 809 Robertson, N., M. Rappas, A. S. Doré, J. Brown, G. Bottegoni, M. Koglin, J. Cansfield, A. Jazayeri,
810 R. M. Cooke and F. H. Marshall (2018). Structure of the complement C5a receptor bound to
811 the extra-helical antagonist NDT9513727. *Nature* **553**: 111.
- 812 Rodríguez, D., A. Ranganathan and J. Carlsson (2015). Discovery of GPCR Ligands by Molecular
813 Docking Screening: Novel Opportunities Provided by Crystal Structures. *Current Topics in*
814 *Medicinal Chemistry* **15**(24): 2484-2503.
- 815 Seow, V., J. Lim, A. J. Cotterell, M.-K. Yau, W. Xu, R.-J. Lohman, W. M. Kok, M. J. Stoermer, M.
816 J. Sweet, R. C. Reid, J. Y. Suen and D. P. Fairlie (2016). Receptor residence time trumps drug-
817 likeness and oral bioavailability in determining efficacy of complement C5a antagonists.
818 *Scientific Reports* **6**: 24575.

- 819 Shi, L., M. Quick, Y. Zhao, H. Weinstein and J. A. Javitch (2008). The Mechanism of a
820 Neurotransmitter:Sodium Symporter—Inward Release of Na⁺ and Substrate Is Triggered by
821 Substrate in a Second Binding Site. *Molecular Cell* **30**(6): 667-677.
- 822 Shimada, I., T. Ueda, Y. Kofuku, M. T. Eddy and K. Wüthrich (2018). GPCR drug discovery:
823 integrating solution NMR data with crystal and cryo-EM structures. *Nature Reviews Drug*
824 *Discovery*.
- 825 Siciliano, S. J., T. E. Rollins, J. DeMartino, Z. Konteatis, L. Malkowitz, G. Van Riper, S. Bondy, H.
826 Rosen and M. S. Springer (1994). Two-site binding of C5a by its receptor: an alternative binding
827 paradigm for G protein-coupled receptors. *Proceedings of the National Academy of Sciences*
828 **91**(4): 1214-1218.
- 829 Sulchek, T., R. W. Friddle and A. Noy (2006). Strength of Multiple Parallel Biological Bonds.
830 *Biophysical Journal* **90**(12): 4686-4691.
- 831 Sulchek, T., R. W. Friddle and A. Noy (2006). Strength of Multiple Parallel Biological Bonds.
832 *Biophys. J.* **90**(12): 4686-4691.
- 833 Ward, P. A. (2004). The dark side of C5a in sepsis. *Nature Reviews Immunology* **4**: 133.
- 834 Wildling, L., B. Unterauer, R. Zhu, A. Rupprecht, T. Haselgrübler, C. Rankl, A. Ebner, D. Vater,
835 P. Pollheimer, E. E. Pohl, P. Hinterdorfer and H. J. Gruber (2011). Linking of Sensor Molecules
836 with Amino Groups to Amino-Functionalized AFM Tips. *Bioconj. Chem.* **22**(6): 1239-1248.
- 837 Wildling, L., B. Unterauer, R. Zhu, A. Rupprecht, T. Haselgrübler, C. Rankl, A. Ebner, D. Vater,
838 P. Pollheimer, E. E. Pohl, P. Hinterdorfer and H. J. Gruber (2011). Linking of Sensor Molecules
839 with Amino Groups to Amino-Functionalized AFM Tips. *Bioconjugate Chemistry* **22**(6): 1239-
840 1248.
- 841 Williams, P. M. (2003). Analytical descriptions of dynamic force spectroscopy: behaviour of
842 multiple connections. *Analytica Chimica Acta* **479**(1): 107-115.
- 843 Woodruff, T. M., K. S. Nandakumar and F. Tedesco (2011). Inhibiting the C5–C5a receptor axis.
844 *Molecular Immunology* **48**(14): 1631-1642.
- 845 Woodruff, T. M., A. J. Strachan, S. D. Sanderson, P. N. Monk, A. K. Wong, D. P. Fairlie and S. M.
846 Taylor (2001). Species Dependence for Binding of Small Molecule Agonist and Antagonists to
847 the C5a Receptor on Polymorphonuclear Leukocytes. *Inflammation* **25**(3): 171-177.
- 848 Yuan, X., S. Raniolo, V. Limongelli and Y. Xu (2018). The Molecular Mechanism Underlying
849 Ligand Binding to the Membrane-Embedded Site of a G-Protein-Coupled Receptor. *Journal of*
850 *Chemical Theory and Computation* **14**(5): 2761-2770.
- 851


852 **Figures**

853




854

855 **Figure 1. FD-based AFM mapping of C5aR receptors and probing their orientation within the lipid bilayer. (A)**
856 Orientation of lipid bilayer-embedded C5aR is random: they can adopt two orientations, with either the
857 intracellular C-terminal His₆-tag or the extracellular N-terminal side facing up. **(B)** In FD-based AFM, the force
858 acting on the cantilever and the distance travelled by the AFM tip are monitored and transformed into a force-
859 distance curve. The applied force is used as feedback during the measurement and the adhesion force is measured
860 as the minimum force in the retraction cycle. **(C)** Overview AFM topography image (height map) of C5aR
861 reconstituted in liposomes and adsorbed on freshly cleaved mica. Sparsely distributed C5aR particles can be
862 observed protruding from the liposomes. Inset: expanded view of a single C5aR particle. The image was acquired
863 with a bare AFM tip. **(D)** Cross-section (white dashed line in C) showing a C5aR particle protruding 1.7 nm from
864 the lipid bilayer having a diameter of 16 nm. The diameter was measured as full width at half maximum (FWHM).
865 **(E)** 2D-histogram of height and diameter of C5aR receptors imaged in C. The diameter distribution shows three
866 main populations, while the height distribution shows two main peaks. Data in C and E are representative of at
867 least five independent experiments.




868
 869 **Figure 2. Multiplex probing of C5aR intra- and extracellular binding sites as a method discriminate C5aR orientation**
 870 **within lipid membrane.** (A, E) Schematic representation of the multiplex experimental setup. Two different AFM
 871 tip chemistries were used to target either the His₆-tag C-terminal end of C5aR using *tris*-NTA-Ni²⁺ functionalized
 872 AFM tips (A-D) or the N-terminal end of C5aR using the endogenous C5a ligand (E-H). (B, C, F, G) AFM topography
 873 and adhesion images were recorded over the same lipid patch with a *tris*-NTA-Ni²⁺ tip (B and C) and a C5a ligand
 874 tip (F and H). (D, H) Representative FD curves showing either no/unspecific interactions (curves 1 and 2) or specific
 875 adhesion events (curve 3) were extracted from the adhesion maps in (C) and (G) and displayed in (D) and (H),
 876 respectively. (I, J) 2D-histograms of force vs height for C5a modified tips (I) and *tris*-NTA-Ni²⁺ tips (J). (K) Height
 877 distribution of the receptors interacting with the *tris*-NTA-Ni²⁺ or the C5a tip. Two populations can be clearly
 878 distinguished, one below 1.75 nm in height, where C5a tips mostly interact with the extracellular side of C5aR,
 879 and another one above 3.5 nm in height, where NTA-Ni²⁺ functionalized tips interact with the intracellular side of C5aR.
 880 (L) Overlay of the height map region marked by the white square in F and the corresponding specific adhesion
 881 events extracted from the same areas in the maps in C and G. Adhesion events between the C5a ligand and the
 882 N-terminal side of C5aR are shown as green dots, while the events rising from the *tris*-NTA-Ni²⁺ AFM tip
 883 interaction with the His₆-tagged C-terminal side of C5aR are displayed as red dots. White circles mark receptors
 884 with a height less than 1.75 nm, highlighting that C5a ligand only interact with the N-terminal side of. The overlay
 885 image shows how the orientation of single C5aR particles can be identified using our multiplex probing method. Data
 886 are representative of at least three independent experiments. Data in K is displayed as mean ± S.D. and the ANOVA
 887 OneWay Tukey test was used to report the statistical significance: *** p<0.001. Data are representative of three
 888 independent experiments.




889
890

891 **Figure 3. Probing the kinetic and thermodynamic parameters underlying C5a ligand binding to C5aR.** (A) Two-site
892 binding model of the C5a-C5aR interaction: the binding site (BS) at its N-terminus (shaded in blue) and the
893 functionally important effector site (ES) at the extracellular region (shaded in red). Sulfonated residues (SO₃⁻) at
894 the BS and Arg (R) residue at the C-terminal of the C5a ligand are thought to play a key role in stabilizing the
895 interaction. (B) Height image and adhesion maps (C) recorded while probing C5aR embedded in the lipid bilayer
896 with a C5a modified AFM tip. (D) The interaction between C5a and C5aR was probed over a wide range of LRs by
897 varying the retraction speed in the force-distance curves. Low LRs were explored at 500 nm s⁻¹ and 2 μm s⁻¹
898 pulling speeds, while high LRs were reached at 50 μm s⁻¹ pulling speed. (E) Extracting the parameters describing
899 the C5a-C5aR free energy landscape. A ligand-receptor bond can be described using a simple two-state model,
900 where the bound state resides in an energy valley and is separated from the unbound state by an energy barrier.
901 The transition state must be overcome to separate ligand and receptor. τ⁻¹(F) and τ⁻¹(0) are residence times linked
902 to the transition rates for crossing the energy barrier under an applied force F and at zero force, respectively. ΔG_{bu}
903 is the free-energy difference between bound and unbound state. (F) Force-volume (FV)-AFM and FD-based AFM
904 were used to explore low LRs and high LRs, respectively. For each pixel of the topography the tip is approached
905 and retracted using a linear (FV-AFM) or oscillating movement (FD-based AFM). (G) A force-distance curve can be
906 displayed as a force-time curve, from which the loading rate can be extracted via the slope of the curve just before
907 bond rupture. (H) DFS plot showing the loading rate-dependent interaction forces of the C5a ligand with C5aR.
908 Data combines rupture forces obtained at lower LRs (10²-10⁵ pN·s⁻¹) and higher LRs (10⁵-10⁷ pN·s⁻¹) Fitting the data
909 using the Friddle–Noy–de Yoreo model (thin grey line) provides average F_{eq}, ΔG_{bu} and residence time (τ_{0.5}) values
910 with errors representing the s.e.m. Each circle represents one measurement. Darker shaded areas represent 99%
911 confidence intervals, and lighter shaded areas represent 99% of prediction intervals. For each condition, data are
912 representative of at least three independent experiments.




913
914

915 **Figure 4. Steered Molecular Dynamics (SMD) or Center-of-mass (COM) pulling simulation of C5aR (WT) – PMX53**
 916 **complex.** (A) Cut-through section of C5aR (WT)-PMX53-POPC system used for equilibrium MD and steered MD
 917 simulations. C5aR is shown in ribbon representation (magenta), embedded in a POPC bilayer (gray) with the
 918 headgroup phosphorous atoms shown in sphere representation and the rest of the lipid molecule shown in wire
 919 representation. TIP3P water molecules are colored blue, Na⁺ ions purple and Cl⁻ ions green. Conformations of
 920 PMX53 at t = 0 ps, t = 500 ps, and t = 1000 ps derived from the COM pulling simulation are shown in orange,
 921 yellow, and dark green colors, respectively. The black arrow is along the z-axis and indicates the direction of pulling
 922 of PMX53. (B) Plot showing force (pN) vs time (ps) profile obtained for the C5aR (WT)-PMX53 system with a pulling
 923 rate of 5 nm/ns. (C) Plot showing the number of intermolecular hydrogen bonds (H bonds) formed/broken
 924 between the ECL2 region (residues 174-196) of C5aR (WT) and PMX53 over the course of the pulling simulation.
 925 (D) Evolution of key intermolecular interactions between C5aR (WT) and PMX53, namely the R6PMX53-D282C5aR
 926 salt-bridge (black), and the R6PMX53-Y258C5aR cation...π interaction (red) over the course of the pulling
 927 simulation. (E) Evolution of key intramolecular interaction R6PMX53-W5PMX53 cation...π interaction (green) in
 928 PMX53 over the course of the pulling simulation. (F) Potential of mean force profile calculated for the dissociation
 929 of PMX53 from C5aR (WT) using WHAM analysis following umbrella sampling simulations for the C5aR (WT)-
 930 PMX53 system. The average PMF profile calculated using bootstrap analysis is presented in the Supplementary
 931 Figure. XX. (G) Position and conformation of PMX53 at t = 0 ps during pulling simulation (pull force = 7.62x10⁻⁵
 932 pN) where R6PMX53 stably and directly interacts with D282C5aR as compared to the conformation observed in
 933 the starting crystal structure conformation. In this conformation, PMX53 forms extensive H bond interactions
 934 (shown as black lines) with the residues of C5aR (WT), especially with residues of ECL2. (H) Position and
 935 conformation of PMX53 at t = 325 ps during pulling simulation (pull force = 2386.14 pN) where key non-covalent
 936 interactions between PMX53 and C5aR (WT) begin to break and R6PMX53 and W5PMX53 are being pulled away
 937 from Y258C5aR and D282C5aR. A number of HBonds between PMX53 and ECL2 also as broken or are in the process
 938 of being broken under the influence of the applied force. (I) Position and conformation of PMX53 at t = 425 ps
 939 during pulling simulation (pull force = 879.08 pN) where the PMX53 molecule has been pulled further away with
 940 the R6PMX53-D282C5aR salt-bridge and the R6PMX53-Y258C5aR cation...π interaction being completely broken.
 941 (J) Position and conformation of PMX53 at t = 600 ps during pulling simulation (pull force = 29.48 pN) where the
 942 ligand is completely unbound from the receptor.



943
944

945 **Figure 5. Probing the kinetic and thermodynamic parameters underlying C5a ligand binding to C5aR at the sub-**
 946 **site level. (A)** Western blot analysis of C5aR sulfonation. Detection of sulfonation of wt C5aR and C5aR Δ Tyr with
 947 Y11F and F14F mutations (C5aR-d2Y). Both constructs are with an N-terminal FLAG tag, which was detected by an
 948 anti-Flag M1 antibody. The two mutations in C5aR Δ Tyr eliminated the sulfonation on C5aR. For each condition,
 949 data are representative of at least three independent experiments. **(B,C)** Exploring C5a binding to the effector
 950 site of C5aR. In **(B)** DFS plot showing the loading rate-dependent interaction forces of the C5a ligand with the C5aR
 951 missing a Tyr residue at the N-terminal end. The DFS plot in **(C)** combines rupture forces obtained at lower and
 952 higher LRs (10²-10⁷ pN·s⁻¹), covering the close-to-equilibrium and far-from-equilibrium binding strengths. **(D,E,F)**
 953 Probing the interactions of the C5a ligand with the C5aR binding site. DFS plots showing the loading rate-
 954 dependent interaction forces of: **(D)** the C5a ligand with C5aR complexed in presence of the PMX53 antagonist,
 955 **(E)** C5a des-ArgC5a des-Arg with C5aR complexed with the PMX53 antagonist and **(F)** DFS plot combining rupture
 956 forces obtained at lower and higher LRs (10²-10⁷ pN·s⁻¹), covering the close-to-equilibrium and far-from-
 957 equilibrium binding strengths. In panels (B,C,D,E,F) fitting the data using the Friddle–Noy–de Yoreo model (thin
 958 lines) provides average F_{eq} , ΔG_{bu} and residence time ($\tau_{0.5}$) values with errors representing the s.e.m. Each circle
 959 represents one measurement. Darker shaded areas represent 99% confidence intervals, and lighter shaded areas
 960 represent 99% of prediction intervals. For each condition, data are representative of at least three independent
 961 experiments.



962
963

964 **Figure 6. Probing the kinetic and thermodynamic parameters underlying ligand binding to C5aR mutants.** (A, B)
965 Dose-response curves of C5a and C5a des-Arg in activating G $_i$ protein through the action on the wtC5aR and C5aR
966 D282A mutant. The activation of G $_i$ protein was determined by measuring the binding of ^{35}S -GTP γS to G $_i$. DFS plots
967 showing the loading rate-dependent interaction forces of the C5a ligand with the C5aR (C), C5a ligand with the
968 C5aR D282A (D), C5a des-Arg interacting with C5aR (E) and C5a des-Arg interacting with C5aR D282A (F). Fitting
969 the data using the Friddle–Noy–de Yoreo model (thin lines) provides average F_{eq} , ΔG_{bu} and residence time ($\tau_{0.5}$)
970 values with errors representing the s.e.m. Each circle represents one measurement. Darker shaded areas
971 represent 99% confidence intervals, and lighter shaded areas represent 99% of prediction intervals. For each
972 condition, data are representative of at least three independent experiments. (G) Cooperative binding of C5a to
973 C5aR though a two-site binding mechanism. Illustration of the free-energy binding landscape of C5a binding to
974 C5aR. ΔG_{bu} gives the free-energy difference between the ligand-bound and unbound states and is indicated for
975 each binding site (BS, ES and BS+ES) by vertical arrows. A positive allosteric interaction is measured when both
976 binding sites (BS and ES) are occupied, as revealed by a significantly higher ΔG_{bu} for the full binding of the C5a.